Sharemaestro Newsreel

Is Rising Earnings Optimism Altering The Investment Case For Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals recently drew attention after analysts became more optimistic about its upcoming August 4, 2026 earnings report, citing a positive Earnings ESP of 18.52% and the company's track record of exceeding consensus in its last two quarters. This shift in sentiment highlights how …

Collegium Pharmaceutical Inc (COLL) Financial Health: Profitability & Balance Sheet Analysis

Collegium Pharmaceutical Inc (COLL) currently has a financial score of 8.88, ranking 29th out of 155 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $193.52 million, an 8.87% increase year-over-year, alongside a …

Collegium Pharmaceutical Inc. (COLL) Q4 2022 Earnings Report - Results, Call & Slides

This report details Collegium Pharmaceutical's (COLL) Q4 2022 earnings. The company reported actual EPS of $1.09, missing the consensus by less than $0.01, and actual revenue of $129.62 million, beating expectations by $4.40 million. The report includes details on the earnings announcement, an audio …

ACB|Aurora Cannabis Inc|Price:2.730|Chg%:+0.060

TradingKey provides a comprehensive stock analysis for Aurora Cannabis Inc (ACB), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status. The analysis notes high institutional ownership and recent "Buy" ratings from analysts, with a target price of $32.00. Despite a sideways …

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has announced that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis Inc. made false and …

BTAI|BioXcel Therapeutics Inc|Price:0.845|Chg%:-0.022

This article provides a comprehensive stock analysis of BioXcel Therapeutics Inc (BTAI), highlighting its relatively stable fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The company is actively developing neuroscience and immuno-oncology candidates, with analysts predominantly rating it as a "Buy" …

Aytu Biopharma Inc (AYTU) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Aytu Biopharma Inc (AYTU) based on its current stock price and financial metrics. As of July 29, 2026, the company's valuation score is 8.95, ranking 65th in the Pharmaceuticals industry, with a P/E ratio of -0.45. Key …

Elanco Animal Health Inc (ELAN) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Elanco Animal Health Inc (ELAN), noting its current score of 8.17, ranking 71 out of 155 in the Pharmaceuticals industry. The company's financial status is described as weak, despite high operating efficiency. Elanco recently reported a …

Earnings call transcript: Tilray posts record fiscal 2026 revenue, shares rise after hours

Supernus Pharmaceuticals (SUPN) Could Be 25% Undervalued On Rising Earnings Expectations

Supernus Pharmaceuticals (SUPN) is considered undervalued by 25% due to rising earnings expectations, with a positive Earnings ESP of 18.52% and a history of beating estimates. Analysts peg the fair value at $62.83, significantly higher than its current share price of $46.98. This valuation …

Supernus Pharmaceuticals (SUPN) Projected to Release Earnings on Tuesday

Pacira Survey: 54% of Workers Report Pain-Related Income Loss

Optimi Health (OPTH) seeks approval for equity plan and new preferred shares

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must (NASDAQ:SIGA)

Tilray Brands (TLRY) Releases Q4 2026 Earnings: Revenue Growth but EPS Miss

Tilray’s 55% YTD Collapse Puts BrewDog and Cannabis Growth Under the Microscope

Tilray Brands, Inc. (TLRY) Reports Q4 Loss, Beats Revenue Estimates

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Posts Quarterly Earnings Results, Hits Estimates

Kiniksa Pharmaceuticals stock rises 2% on raised guidance, revenue beat

Alkermes (ALKS) Reports Break-Even Earnings for Q2

Caring Brands (CABR) interim CFO reports 150,000-share issuer redemption at $1.00

Alkermes (ALKS) Could Be 11% Above Fair Value As Earnings Land】【。

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

Aurora shareholders will vote on four items at Aug. 7 virtual meeting

Institutional Shareholder Services (ISS) has recommended that Aurora Cannabis shareholders vote FOR all resolutions at the upcoming 2026 Annual General Meeting (AGM) on August 7, 2026. Shareholders will vote on fixing the board size at five directors, electing directors, appointing the auditor, and a …

PRGO|Perrigo Company PLC|Price:10.130|Chg%:+0.040

This article provides a comprehensive stock analysis of Perrigo Company PLC (PRGO), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. While institutional ownership is very high and analysts largely rate it as "Hold," the stock price is …

Price to book ratio of United Therapeutics Corporation – HAM:UTH

This page from TradingView displays financial information, specifically the price-to-book ratio, for United Therapeutics Corporation (UTH) on the Hamburg Stock Exchange. The market appears to be closed with no trades showing. The article provides a chart or table for the period, value, and change …

Pacira Biosciences Inc (PCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Pacira Biosciences Inc (PCRX), detailing its current risk score, beta value, and various volatility metrics. The company ranks 49th out of 155 in the pharmaceuticals industry with a risk assessment score of 6.68 and a beta of …

Alvotech SA (ALVO) Cash Flow

This article provides a detailed look at Alvotech SA's (ALVO) cash flow statement, including operating, investing, and financing cash flow data presented quarterly and annually. It includes specific financial figures for these categories over several fiscal quarters, highlighting changes year-over-year. The article also features …

BFRI|Biofrontera Inc|Price:1.050|Chg%:-0.040

This article provides a detailed financial overview of Biofrontera Inc (BFRI), including its latest earnings report from May 14, 2026, with an EPS forecast of -0.12 and revenue forecast of 10.25M. It presents comprehensive quarterly and annual financial statements such as income statements, balance …

Regencell Bioscience Holdings Ltd

This article provides an overview of Regencell Bioscience Holdings Ltd (RGC), including its current stock price, market cap, and stock performance. It notes that revenue breakdown data by business segment and region have not yet been disclosed by the company. The page serves as …

Redhill Biopharma Ltd (RDHL) Institutional Confidence

This article from TradingKey provides an overview of Redhill Biopharma Ltd's (RDHL) institutional confidence, a component of its overall stock score. It lists institutional holdings and changes, showing that while some firms like Yorkville Advisors Global hold significant shares without recent changes, others like …

TherapeuticsMD Inc (TXMD) Income Statement

This article provides a detailed income statement for TherapeuticsMD Inc (TXMD), offering both quarterly and annual financial data spanning several years. It includes key financial metrics such as total revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The page …

Sonoma Pharmaceuticals Inc (SNOA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of the shareholder structure of Sonoma Pharmaceuticals Inc (SNOA), detailing major shareholders and institutional holdings. It lists the proportion of shares held by entities like DRW Securities, Vanguard Capital Management, and Geode Capital Management, as well as various shareholder …

Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Xeris Biopharma Holdings Inc (XERS) has an earnings forecast score of 8.57, ranking 26th in the Pharmaceuticals industry. Analysts have an average price target of $10.00 for XERS, with a consensus "Buy" rating based on 7 analysts. The expected revenue for the next quarter …

Talphera Inc (TLPH) Institutional Confidence

Talphera Inc (TLPH) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 40.00%, showing a 0.70% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.48% of outstanding shares.

Tilray Brands Inc (TLRY) Institutional Confidence

The article discusses the institutional confidence score for Tilray Brands Inc (TLRY), which currently stands at 3.00, ranking 92 out of 155 in the Pharmaceuticals industry. Institutional shareholding is 9.89%, a 16.13% decrease from the previous quarter. The largest institutional shareholder is Bill Nygren …